fda glp-1 warning news november 2025 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System Trends In FDA FY 2025

TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes

Distribution of NPY receptors in the hypothalamus

Q13: Is retatrutide medical advice

dba iVisitDocJulyMDLas Villas Health Care LLC dba Villas HealthLean Dreams LLC dba LeanDreamsLovely Meds, Inc

Despite these findings, to our knowledge, there are no large population-based studies that have investigated the incidence of new-onset major cardiovascular events or clinically significant portal hypertension events in patients with MASLD who are receiving treatment with GLP-1 agonists for any indication

Some people may also receive GLP-1 medications to manage health conditions like type 2 diabetes